Ci3_Logo_EN_CMYK

Cluster for Individualized Immune Intervention (Ci3)
Cluster für Individualisierte ImmunIntervention

Germany: Rhineland-Palatinate
Tobias Neumann

Overview

Profile:
100% completed

About us

The Cluster for Individualized Immune Intervention (Ci3) promotes the development of innovative immunotherapies and diagnostics for serious diseases with an unmet medical need. Its strong network of pharmaceutical and biotechnology companies, universities, and other research institutions is located in the Rhine-Main area, a region with one of Europe’s longest and most successful histories in pharmaceutical innovations. Through the cluster's combined expertise and international collaborations, Ci3 aims to advance personalized medicine by breaking down innovation barriers and enabling disruptive technologies.

Formalised strategy
Strategy focus on internationalisation

Cluster composition

  • 92
    Cluster Members
  • 48
    SME's
  • 21
    Large Companies
  • 23
    Research Organisations, Universities, Technology Centers
  • 0
    Other Ecosystem Actors

Achievements

  • Setting up of an innovative network of partners working in the field of immunoncology, infectious and autoimmune diseases, in particular individualized cancer immunotherapies. Successful implementation of new therapeutic concepts into clinic.
  • Development of innovative bioinformatics tools for individualized and personalized medical approaches. 
  • Connecting SME and research institution with large pharmaceutical companies, translating innovative technologies from basic research into the clinic.

Management team

Tobias Neumann
Cluster Manager

Sectorial and industrial focus

Sectoral Industries
Professional, scientific and technical activities:M72 Scientific research and development - Human health and social work activities:Q86 Human health activities
Technology fields
A\: Human necessities:Medical or veterinary science; hygiene
S3 EU priority areas
Digital transformation:Artificial intelligence, cognitive systems, augmented and virtual reality, visualisation, simulation, gamification & interaction technologies - Digital transformation:Big data, data mining, database management - Digital transformation:e-Health (e.g. healthy ageing)
Cross-sectoral industries
Biopharmaceuticals

Services

Support services provided

Access to the European Internal Market
Access to finance: Public funding
Facilitation of collaboration between members (within the cluster)
Support of Research, Development and Innovation

Support programmes

EU Programmes

European Programmes
H2020

Name & description

Project name

Project 1. Permides: It is the aim of PERMIDES to strengthen the competitiveness and foster the innovation potential of personalized medicine as an emerging industry in Europe by providing key solutions for the reconfiguration of the biopharmaceutical value chain towards a Health Economy 4.0 with a special focus on oncology (i.e. cancer treatment). Current value chain challenges lie in e.g. data gathering and exchange, big data and machine learning, or new software-based marketing methods. Via a cross-clustering approach, leading biopharma and IT clusters from three countries (Austria, Germany, and Norway) will create novel cross-sectoral collaborations between SMEs to address innovation barriers in the biopharma sector via cutting-edge IT solutions. As a cross-cutting industry, the ICT and software sector is an enabler of innovation in many industries and therefore provides a broad knowledge base of processes and best practice solutions in diverse industrial contexts and business environments.

Project 2. Digi-B-Cube (Digital Enterprise Innovations for Bioimaging, Biosensing and Biobanking Industries) The DIGI-B-CUBE project aims to unlock the cross-sectoral collaborative potential of SMEs by combining artificial intelligence (AI) and cognitive computing digital technologies (CCDT) with the bioimaging-biosensing-biobanking (B-CUBE) industries to deliver market sensitive disruptive technologies, and by generating innovative solutions that enhance patient-centred diagnostic work-flows, delivered through the improved algorithms for the efficiency and accuracy of medical diagnostics. DIGI-B-CUBE will study the characteristics in market dynamics & specificities for innovations created by merging AI, CCDT & B-CUBE industries. By providing a framework for a more structured cross-sectoral and cross-border collaboration that manages all of the complex workflows within the process, DIGI-B- CUBE instantiates the mechanisms to ensure long-term sustainability of the action through collaborations of the participating clusters with hospitals, academia, industry, investors, business angels, managing authorities of the national innovation agencies, and the European Commission support measures (such as EIT, ESIF). The main objective of this project is to provide key digital solutions for the reconfiguration of the medical diagnostics value chain towards a Health Economy 4.0 with a special focus on the biobanking, bioimaging and biosensing industries. Activities financed by the ESIF in the participating regions as part of the Smart Specialisation Strategies will be bundled in cooperation with the responsible managing authorities in addition to the innovation voucher scheme for SMEs. By integrating innovations in IT into bioimaging, biosensing and biobanking industries, this project will accelerate the goal of personalised medicine that can eventually offer patients a fast and efficient diagnosis-treatment-healthcare system.

Cooperation activities

International cooperation

Targeted countries

Transnational cooperation

Targeted countries

Austria
Greece
Portugal
Spain

Transnational support activites

- none -

International support activites

Promotional Activities

Upcoming events

Monday Tuesday Wednesday Thursday Friday Saturday Sunday
29
30
31
1
2
3
4
 
 
 
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
 
 

Latest news and documents

There is no uploaded content...